# Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

> **NCT04005144** · PHASE1 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 3 (actual)

## Conditions studied

- ALK Gene Rearrangement
- Lung Non-Small Cell Carcinoma
- Progressive Disease
- ROS1 Gene Rearrangement
- Stage IIIB Lung Cancer
- Stage IIIC Lung Cancer
- Stage IV Lung Cancer
- Stage IVA Lung Cancer
- Stage IVB Lung Cancer

## Interventions

- **DRUG:** Binimetinib
- **DRUG:** Brigatinib

## Key facts

- **NCT ID:** NCT04005144
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-25
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low Accrual
- **Last updated:** 2022-10-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04005144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04005144, "Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04005144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*